Human breast tumors contain significant amounts of stromal cells. There exists strong evidence that these stromal cells support cancer development and progression by altering various pathways (e.g. downregulation of tumor suppressor genes or autocrine signaling loops). Here, we suggest that stromal carcinoma-associated fibroblasts (CAFs), shown to be generated from bone marrow-derived mesenchymal stem cells, may (i) recycle tumor-derived lactate for their own energetic requirements, thereby sparing glucose for neighboring glycolytic tumor cells, and (ii) subsequently secrete surplus energetically and biosynthetically valuable metabolites of lactate oxidation, such as pyruvate, to support tumor growth. Lactate, taken up by stromal CAFs, is converted to pyruvate, which is then utilized by CAFs for energy needs as well as excreted and shared with tumor cells. We have interrogated lactate oxidation in CAFs to determine what metabolites may be secreted, and how they may affect the metabolism and growth of MDA-MB-231 breast cancer cells. We found that CAFs secrete pyruvate as a metabolite of lactate oxidation. Further, we show that pyruvate is converted to lactate to promote glycolysis in MDA-MB-231 cells and helps to control elevated ROS levels in these tumor cells. Finally, we found that inhibiting or interfering with ROS management, using the naturally occurring flavonoid phloretin (found in apple tree leaves), adds to the cytotoxicity of the conventional chemotherapeutic agent doxorubicin. Our work demonstrates that a lactate-pyruvate, reciprocally-supportive metabolic relationship may be operative within the tumor microenvironment (TME) to support tumor growth, and may be a useful drug target.
Introduction
The Warburg effect, which describes the dependence of tumors on glucose and constitutive aerobic glycolysis, results in the accumulation of cellular lactate as a metabolic byproduct [1, 2] . The excess lactate is evacuated from the tumor cell to prevent intracellular acidosis and subsequent apoptosis [3] [4] [5] . To facilitate the trafficking of lactate and other monocarboxylic acids, tumor cells and normal tissue express a family of proton-coupled monocarboxylate transporters (MCTs) [6, 7] . Specifically, it has been shown that lactate, secreted via low-affinity MCT4 in white, fast-twitch glycolytic myocytes, is taken up through high-affinity MCT1 in neighboring red, slow-twitch oxidative muscle fibers, wherein the metabolite is used to drive energy production [7] . These studies were first evidence of the existence of lactate shuttles and have collectively characterized MCT1 and MCT4 proteins as respective net importers and exporters of lactate [8] . A compelling finding of these investigations is that MCT4/MCT1-mediated lactate shuttles allow oxidative muscles to utilize lactate preferentially over glucose, thereby sparing it for the more glycolytic myocytes [7, 8] . Subsequent studies demonstrated the existence of such cell-cell lactate shuttles in astrocytes and neurons [9] and in sperm [10] . Investigations of intercellular metabolic complementarity in pathological systems have suggested that such lactate shuttles may be operative in tumors. Indeed, a recent report indicates that glycolytic triple negative basal breast adenocarci- CAFs take up and metabolize lactate as well as secrete lactate oxidation metabolites, as shown by 13 C MR spectroscopy on cell extracts and CCM. Signal assignments are: α-KG -α-ketoglutarate, Gluglutamate; Ala -alanine; Lac -lactate; Pyr -pyruvate; α-Glc & β-Glc -α-glucose and β-glucose; "-C" followed by number -position of 13 C labeling as a result of metabolic conversion of exogenous 10 mM 3-13 C-L-lactate. ** p < 0.005, *** p < 0.0005 by two-tailed, unpaired, unequal variance Student's T-test; Abbreviations: MDAs -MDA-MB-231 cells; MSCs: human mesenchymal stem cells; CAFs: cancer-associated fibroblasts; CCM -CAF-conditioned medium. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] noma MDA-MB-231 cells secrete lactate that is then taken up by oxidative luminal breast adenocarcinoma MCF-7 cells (MCFs) for conversion to pyruvate [11] . Other recent data suggest that the interplay between tumor and carcinoma-associated fibroblasts (CAFs) is more complex and that tumor cells may induce aerobic glycolysis in CAFs as a result of oxidative stress through secretion of hydrogen peroxide [12] . Tumor and tumor-associated stromal cells have the ability to adapt to oxidative stress, induced by increased production of cellular reactive oxygen species (ROS), by shifting oxidative mitochondrial metabolism toward glycolytic metabolism [13, 14] . Human breast tumors have been shown to contain a significant number of stromal cells [15] and extensive evidence indicates that these stromal cells support tumor growth [16] . Although numerous mechanisms have been suggested [12, [17] [18] [19] , the mechanisms underpinning this relationship remain unclear. As tumors secrete significant amounts of lactate into the stroma, we had previously hypothesized that, in addition to preventing intracellular acidosis, this excreted lactate may serve to help recruit stromal components for tumor development [20] . We have demonstrated that lactate is taken up by stromal CAFs, and subsequently utilized for energy needs [20] . We now extend our original hypothesis to propose that stromal CAFs may (i) recycle tumor-derived lactate for their own energetic needs, thereby sparing glucose for the neighboring glycolytic tumor cells, and (ii) subsequently secrete energetically and biosynthetically valuable metabolites of lactate oxidation, such as pyruvate, to support tumor cell growth. As ROS modulation is linked to a shift in cellular metabolic pathways [13, 14] , we hypothesize that (i) metabolic cooperation between tumor and stromal cells also modulates ROS levels and (ii) modulating ROS production by inhibitors acting across several pathways has the ability to attenuate ROS levels and glycolysis in tumor cells. Using ROS inhibitors with broad activity may also promote future clinical translation as an adjuvant to chemotherapy.
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The current study interrogated lactate oxidation in CAFs to identify secreted metabolites and determine how they may affect the metabolism and growth of MDA-MB-231 cells. We found that CAFs secrete pyruvate as a metabolite of lactate oxidation. Further, we show that pyruvate is converted to lactate to promote glycolysis in MDA-MB-231 cells, and helps to control elevated reactive oxygen species (ROS) levels in these tumor cells. Finally, we report that flavonoid-mediated inhibition of or interference with MCT function and ROS management adds to the cytotoxicity of doxorubicin, a conventional chemotherapeutic agent widely used in treatment of breast cancer [21] . Our work demonstrates that a lactate-pyruvate, reciprocally-supportive metabolic relationship may be operative within the tumor microenvironment (TME) to support tumor growth.
Materials and methods

Cell culture
The breast cancer cell line MDA-MB-231 was purchased from ATCC (Manassas, VA). Bone marrow-derived mesenchymal stem cells (MSCs) were purchased from Lonza Walkersville, Inc. (Walkersville, MD; Lonza Group Ltd.). All cells were maintained in Dulbecco's Modified Essential Medium (DMEM, Sigma-Aldrich, St. Louis, MO), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin, at 37°C and 5% CO 2 in a humidified atmosphere. The complete culture medium contained 25 mM glucose, 4 mM glutamine and no pyruvate. Trace amounts of lactate are present in culture medium from glucose. The pyruvate concentrations used for the experimental studies ranged from 0 mM to 5 mM, based on the study published by Diers et al. [22] .
CAF production
Medium from MDA-MB-231 cells growing at 70-80% confluence was collected and centrifuged at 200×g for 7 min. The supernatant was transferred to a new tube, centrifuged as before, and subsequently filtered through a 0.2 µm membrane. For the purposes of this study, this filtrate was termed tumor-conditioned medium (TCM). The medium of MSCs growing at 60-70% confluence was replaced with TCM every 12 h for 10 days or every 24 h for 20-30 days to induce the CAF-like state [23] . For the purposes of this study MSCs and CAFs are collectively termed stromal cells.
Extracellular acidification rate (ECAR) and basal oxygen consumption rate (OCR) measurements
The ECAR and OCR of CAFs and MDA-MB-231 cells (Fig. 1A,  Supplementary Figure) were determined using a Seahorse XF96 Analyzer as per manufacturer's instructions. Briefly, 20,000 cells/well (for cell number titration experiments 10,000 (10k), 20,000 (20k), and 40,000 (40k) cells/well respectively) were seeded into XF96 PET cell culture microplates (Part #101104-004, Seahorse Bioscience, North Billerica, MA). On the same day, the sensor cartridge was preincubated in XF96 calibrant solution (Par #100840-0000, Seahorse Bioscience, North Billerica, MA) in an XF Prep Station. Twenty-four hours later media in the XF96 PET plates were aspirated. Cells were washed one time with 100 µL phosphate buffered saline (PBS)/well and subsequently treated with 150 µL/well DMEM deficient in FBS and sodium bicarbonate, containing 1% penicillin/streptomycin, pH 7.4, in an XF Prep Station for 20 min. The ECAR and OCR of cells were then monitored for approximately 30-60 min at intervals of approximately 5-8 min.
Lactate concentration in cell-conditioned media
Three hundred thousand CAFs or MDA-MB-231 cells per well were seeded into 24-well plates in 10 mM glucose-containing complete medium. Conditioned media were collected from each well twentyfour hours after growth and centrifuged at 200×g RCF for 5 min. Twenty microliters of each sample were then applied to a lactate test strip and the lactate concentration determined, using a lactate analyzer (Hoffman-La Roche Ltd., Roche Diagnostics, USA) in accordance to the manufacturer's instructions. The concentration was normalized to 1· 10 5 cells to account for differences in the number of cells conditioning the medium.
Glucose concentration in cell-conditioned media
Three hundred thousand CAFs or MDA-MB-231 cells per well were seeded into 24-well plates in 10 mM glucose-containing complete medium. Conditioned media were collected from each well twentyfour hours after growth and centrifuged at 200×g RCF for 5 min. Three microliters of each sample were then applied to a glucose test strip and the glucose concentration measured, using the GlucCell Glucose Monitoring System (Chemglass Life Sciences, Vineland, NJ) according to manufacturer's instructions. The concentration was normalized to 1· 10 5 cells to account for differences in the number of cells conditioning the medium.
Glucose uptake assay
Seventy-five thousand MSCs, CAFs, or MDA-MB-231 cells per well were seeded into 12-well plates. After attachment and growth for 24 h (Fig. 1C) C]-pyruvate in 200 µL lactate uptake buffer (LUB: 10 mM HEPES, 5 mM KCl, 1 mM MgCl2, 150 mM NaCl, 1 mM CaCl2, pH 7.5) per well at 37°C and 5% CO 2 . All cells were subsequently washed with 500 µL ice-cold LUB to stop transport. Cells were then exposed to 200 µL 0.025% Trypsin /0.53 mM EDTA per well for 15 min at 37°C and 5% CO 2 . The entire content of each well was placed into scintillation liquid and counted in a scintillation counter to generate CPM. Where appropriate, CPM was normalized to 100,000 cells. In co-culture experiments (Fig. 4A ), 5·10 4 MDA-MB-231 cells were seeded into the chambers of a Boyden chamber plate and 10 5 MDA-MB-231 cells or CAFs were seeded into the inserts. Cells were co-cultured for 4 days, after which MDA-MB-231 cells in chambers were assayed to determine pyruvate uptake as described above.
Reverse transcriptase polymerase chain reaction (RT-PCR)
The expression of several genes involved in the production or management of reactive oxygen species (ROS) was evaluated by RT-PCR. To assess glucose 6-phosphate dehydrogenase (G6PD) mRNA expression (Fig. 5C) the spectra. The spectra in A and B were normalized to the DSS signal (0.05 ppm to −0.05 ppm), accounting for differences in sample volume (3 mm and 5 mm tubes) and shim quality, followed by scaling with the depicted factor (beside cell number) to account for differences in cell number between samples. Signal assignments with the number following "-C" depicting the position of the incorporated 13 C carbon labelare: Lac -lactate; Glc -glucose (natural abundance); Glu -glutamate; Gln -glutamine; Pyr -pyruvate; ParaPyr -parapyruvate; Aceacetate; Ala -alanine; Orange *-Pyr-C3(OH); ** Possibly Acetoacetate-C2;? Unassigned signal. Note: The Ace-C2 signal may overlap with a GABA-C3 signal, and thus, these two may not be distinguishable. After applying a 1 Hz exponential line-broadening filter, the free induction decays were Fourier transformed, zero filled, phase corrected, and baseline corrected by Bernstein polynomial fit. The reference standard sodium 2,2-dimethyl 2-silapentane-5-sulfonate (DSS) was set to 0.015 ppm (ppm). Signals were assigned to metabolites based on their 13 C chemical shift. The number behind "-C" depicts the position of the 13 C-labeled carbon in each metabolite.
Cell growth assay
For the cell growth studies displayed in Fig. 2A -B, fifty thousand MDA-MB-231 cells per well were seeded into 12-well plates in triplicate. Twenty-four hours later, cells were washed with 1X PBS and exposed for 5 days to 5 mM of either α-alanine, β-alanine, GABA, acetate or pyruvate (sodium pyruvate) in the absence or presence of 2.5 mM glucose, after which cells were harvested by trypsinization and counted via Trypan Blue exclusion assay, using a ViCell Cell Viability Analyzer (Beckman Coulter, Indiananpolis, IN). The total number of viable cells for each condition was normalized to the number viable cells for the depleted condition (glucose-depleted medium with no added alanine, GABA, acetate or pyruvate). Pyruvate was added essentially as done by Diers et al. [22] . To assess cell growth inhibitory effects of various flavonoids on MDA-MB-231 cells (Fig. 6B ), 1.5×10 5 cells were seeded into 12-well plates in triplicate. Twenty-four hours later, cells were treated with 100 µM Phloretin, Phloredzin, Quercetin, Isoquercetin, or p-Phenylenediacetic acid. Cells were harvested 6 days later for cell counting via Trypan blue exclusion (ViCell). To investigate the combined cytotoxicity of the chemotherapy drug doxorubicin and Phloretin, 3×10 5 cells were seeded into 12-well plates in triplicate and treated after 24 h attachment with 100 µM Phloretin, 5 nM doxorubicin each alone or both combined in the presence of absence of CCM for 6 days, followed by harvest and cell counting (Fig. 6G ).
Reactive oxygen species detection assay
Fifty thousand cells/well were seeded into black, clear-bottom, 96-well plates. After 24 h, ROS were quantified, using a 2′,7′-dichlorofluorescein diacetate (DCFDA) Cellular ROS Detection Kit (Abcam®, Cambridge, MA) as per manufacturer's protocol. Briefly, cells were washed once with 200 µL/well of 1X assay buffer solution and subsequently incubated with 100 µL/well of 25 µM DCFDA in 1X assay buffer at 37°C and 5% CO 2 for 45 min. Afterwards, all wells were washed with 1X assay buffer as before, followed by treatment with 100 µL 1X assay buffer/well with or without indicated drug or nutrient for indicated duration. At each time point, plates were read in a fluorometer at an excitation wavelength of 485 nm and at an emission wavelength of 535 nm. Statistically significant change in fluorescence relative to controls was considered to be a significant change in amount of intracellular ROS. In co-culture experiments (Fig. 5D) 
Glutathione assay
In co-culture experiments (Fig. 5F ), 5·10 4 MDA-MB-231 cells were seeded into the chambers of a Boyden chamber plate and 10 5 MDA-MB-231 cells or CAFs were seeded into the inserts. Cells were cocultured for 4 days, after which MDA-MB-231 cells in chambers were assayed for intracellular, reduced glutathione (GSH) levels using a Glutathione Colorimetric Assay Kit (# K261-100, BioVision Inc., Milpitas, CA) as per manufacturer's protocol. Briefly, cells were washed once with 1X PBS and centrifuged at 600×g RCF for 5 min and lysates prepared as per manufacturer's protocol. Two to 10 µL of lysate supernatant of each sample were used to determine the GSH detection limit of the kit in a 96-well plate. The volume of lysate corresponding to the linear detection range of the GSH standard curve was used for downstream data transformation. Sample absorbance values (optical density, OD) were determined at 405 nm. Statistically significant change in OD relative to controls (P≤0.05, unpaired t-Test) was considered to be a significant change in amount of GSH.
Results
CAFs are functionally less glycolytic than MDA-MB-231 cells
In this study, we used metastatic, triple negative (null for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor) MDA-MB-231 breast cancer cells. These cells are dependent on stromal support for in vivo growth [16] , implicating the presence of a metabolic relationship between MDA-MB-231 cells and their TME. Further, our hypothesis regarding metabolic complementarity between tumor cells and CAFs indicate that the latter are important constituents of the TME, and predict that the former are more glycolytic than the latter [20] . Thus, it was of interest to directly compare the glycolytic profiles and mitochondrial respiration of the two cell types.
We measured the ECAR of MDA-MB-231 cells and CAFs via a Seahorse XF96 Analyzer, which enables real-time monitoring of the rate of cellular proton excretion (mpH/min), and therefore, provides a measure of glycolysis. As indicated in Fig. 1A to that of cell lines of lesser metastatic potential [25] . Further, the consistently higher basal OCR values in MDA-MB-231 cells compared to CAFs at equal cell numbers indicates higher mitochondrial respiration in MDA-MB-231 cells than in CAFs (Supplementary Figure  (Bottom) ). These results indicate that MDA-MB-231 cells are more metabolically active than CAFs. It has been shown that MDA-MB-231 cells secrete more lactate than MCF-7 cells under both normoxic and hypoxic conditions [11] , thereby confirming reports of MDA-MB-231 cells' high glycolytic metabolism [2, 26] . We compared the lactate production of CAFs and of MDA-MB-231 cells to gain insight into the relative oxidative or glycolytic metabolism of each cell type. We found that the lactate output of MDA-MB-231 cells is approximately 2-fold greater than that of CAFs (Fig. 1B and [20] ). To more accurately profile differences in glucose consumption between MDA-MB-231 cells and CAFs, a glucose analyzer was used to quantify the remaining glucose in the media of cells after they had been incubated for 24 h in glucose-replete, complete medium. The glucose concentration of CAF media was almost unchanged relative to its initial concentration of 10 mM, while the glucose concentration of MDA-MB-231 medium dropped by more than 2 fold (Fig. 1B) , suggesting that MDA-MB-231 cells consume more glucose than CAFs. In agreement with such glycolytic flux differences, MDA-MB-231 cells show significantly higher glucose transport than the stromal cells (Fig. 1C) . Coupled with the ECAR results, these data indicate that MDA-MB-231 cells are significantly more glycolytic than CAFs, and implicate a potential crosssupportive lactate source -lactate sink (MDA-MB-231 cells -CAFs) relationship.
CAFs secrete several lactate-oxidation metabolites (LOMs)
We have shown that CAFs and MSCs take up lactate and oxidize it for energetic purposes ( Fig. 1D and [20] ). Using 1 H-decoupled 13 C MRS of CCM collected from CAFs grown for 24 h in medium containing 10 mM 3-13 C-L-lactate, we identified signals specific to alanine, γ-aminobutyric acid (GABA), acetate, and pyruvate (Fig. 1D) . The presence of acetate and alanine is not unexpected, as these are immediate downstream metabolites of pyruvate, which is an immediate metabolite of lactate oxidation. As the signal of GABA labeled in C3 may overlap with acetate-C2, there is the possibility that lactate may be converted to butyric acid in CAFs. The latter may occur via the cycling of lactate-derived pyruvate through the tricarboxylic acid cycle (TCA), yielding α-ketoglutarate (α-KG), an intermediate that is transaminated to glutamate as evidenced by the labeling of glutamate in the C4 position (Glu-C4), and which subsequently may be metabolized to GABA. Although studies have shown that bone marrow stromal cells have the potential to synthesize GABA de novo when appropriately differentiated [27] , the data in Fig. 1D may be the first indication of the presence of metabolically-derived GABA in stromal cells. Collectively, these results support our previous finding that lactate is metabolized oxidatively in CAFs. Additionally, these data suggest that CAFs secrete LOMs that may be of energetic and/or biosynthetic value to neighboring tumor cells or other cell types (e.g. immune cells) in the TME.
Pyruvate synergistically increases MDA-MB-231 cell growth in the presence of glucose
The presence of LOMs in the medium of 3-13 C-L-lactate-treated
CAFs suggests that lactate shuttling from MDA-MB-231 cells to CAFs may lead to reciprocal metabolic support of the former by the latter. To determine the functional value of LOMs to MDA-MB-231 cells, we profiled their growth in the presence or absence of α-alanine, β-alanine, GABA, acetate, or pyruvate. As glucose is a limiting nutrient in the TME, it was of interest to determine the contribution of exogenous LOMs to MDA-MB-231 cell growth within or without the context of minimal glucose (2.5 mM). Interestingly, alanine, GABA, and acetate had no effect on MDA-MB-231 cell growth in the absence of glucose, while only α-alanine appeared to show a modest growth benefit in the presence of glucose ( Fig. 2A) . Pyruvate (2.5 mM) increased the growth of MDA-MB-231 cells by approximately 1.7 fold, and in the presence of 2.5 mM glucose increased their growth synergistically (Fig. 2B) . To ensure that pyruvate-mediated growth of MDA-MB-231 cells in the presence of glucose was not simply due to an increase in glucose uptake, we tested the uptake of 14 C-D-glucose with or without pyruvate. We found that pyruvate did not affect glucose uptake in MDA-MB-231 cells (Fig. 2C) . This is consistent with our observation that simply increasing the glucose concentration in the culture medium does not affect MDA-MB-231 cell growth kinetics (data not shown). That pyruvate per se moderately increased MDA-MB-231 growth was expected, as the monocarboxylate may serve as a potential energetic and biosynthetic source of carbon. However, its synergy, rather than simple additivity, with glucose in promoting MDA-MB-231 cell growth indicates that exogenous pyruvate may partially relieve the requirement of MDA-MB-231 cells to route glucose to produce energy via canonical glycolysis. This may increase the bioavailability of glucose to biosynthetic routes, such as anaplerosis or the pentose phosphate pathway. Thus, CAF-secreted pyruvate may help to balance energetic and biosynthetic demands of the tumor cells, especially when glucose is limited, to robustly increase MDA-MB-231 cell growth.
MDA-MB-231 cells take up pyruvate for glycolytic and biosynthetic needs
The increase in MDA-MB-231 cell growth by pyruvate suggested that the monocarboxylate was internalized to support the metabolic needs of the tumor cells. To directly test the fate of pyruvate in MDA-MB-231 cells, we exposed them to 5 mM 13 C-pyruvate for 24 h in the presence of varying glucose concentrations and subsequently subjected cellular extracts and culture media (TCM and control) to 13 C protondecoupled magnetic resonance (MR) analysis. The incorporation of the 13 C label into specific carbon positions of downstream metabolites permits one to identify which metabolic pathways define the metabolic fate of pyruvate [28, 29] . Low levels of intracellular glucose were detected in extracts from MDA-MB-231 cells exposed for 24 h to medium containing glucose (Fig. 3A pink shaded area marked with Glc, natural abundance). Intracellular glucose also leads to the metabolic conversion of unlabeled glucose-derived pyruvate in the TCA cycle, as evidenced by the appearance of intracellular lactate derived from 13 Clabeled pyruvate, which is not visible when glucose is absent or limited (Fig. 3A) . The pyruvate-derived 13 C labeling of glutamate and glutamine in all medium conditions demonstrates the uptake and metabolic conversion of pyruvate in the TCA cycle (Fig. 3A, B) . The presence of α-KG in MDA-MB-231 cell extracts (Fig. 3A) indicates that some pyruvate may have entered the TCA cycle for anaplerotic purposes. Although a small portion of pyruvate does shunt into the TCA cycle in MDA-MB-231 cells, most is converted to lactate and excreted extracellularly. Accordingly, the signal intensity of pyruvate-derived lactate is high in the TCMs (Fig. 3B) . The labeling of alanine in the C3 position is higher in glucose-free TCM than in TCM supplemented with glucose (Fig. 3B) . The 13 C labeling of lactate in the C2 and C1 position did not change significantly in response to glucose deprivation (Fig. 3B) . Increased use of pyruvate for the TCA cycle in glucose-free medium compared to glucose-containing media is supported by (i) the increased ratio of 13 C-labeled glucose and glutamine to lactate-C3 and (ii) the lower pyruvate-derived lactate-C3 and higher acetate-C2, relative to 3-13 C-pyruvate (Fig. 3B) .
These data are supported by control media sample data (Fig. 3C ), which show no spectral differences aside from glucose signal levels. In addition to the strong 3-13 C-labeled pyruvate signal in the control media, several natural abundance 13 C signals of medium components can be identified; of note is that control media typically contain low levels of lactate ( < 1 mM, Fig. 3C ). The presence of parapyruvate in control media samples is from the non-enzymatic conversion of pyruvate to parapyruvate in aqueous solutions [30] . Parapyruvate disappears as the cells metabolize pyruvate, indicating the reversion of the non-enzymatic reaction that produced it in the control media (Fig. 3B, C) . Exogenous pyruvate (5 mM, which is higher than the 0-1 mM typically contained in culture media) does not fully recapitulate the MDA-MB-231 growth potential of glucose, as evidenced by the decrease in cell number and concomitant with the decrease in glucose concentration in the medium (Fig. 3A) and consistent with results in Fig. 2B . As indicated by the absence of glucose signals, MDA-MB-231 cells metabolize 5 mM glucose within the 24 h incubation period (Fig. 3B) , suggesting that MDA-MB-231 cells depend significantly on glucose to support their metabolic and energetic needs. Further, exposure of MDA-MB-231 cells to CCM from CAFs in a Boyden chamber co-culture system increased pyruvate uptake (Fig. 4A) , the expression of glucose transporter 1 (GLUT1), glucose transporter 3 (GLUT3), lactate exporter MCT4 (not shown), and glucose uptake (Fig. 4B) in these tumor cells. These data collectively indicate that pyruvate and other CCM factors may support and amplify glycolysis in MDA-MB-231 cells.
In MDA-MB-231 cells, alanine and glutamate are most commonly synthesized by exogenous glutamine via the TCA. These cells are reliant on exogenous glutamine as they do not express glutamine synthetase and therefore do not undergo do novo glutamine synthesis [31] . Glutamine is the major contributor to anaplerotic flux in the TCA of these cells [32] and when deprived of this amino acid, MDA-MB-231 cells are forced to use pyruvate carboxylase to form TCA intermediates necessary for biosynthesis [33, 34] . Pyruvate carboxylase shunts pyruvate into the anaplerotic, non-oxidative route of the TCA [35] . Although we did not detect 13 C-labeled alanine in cell extracts of MDA-MB-231 cells treated with 13 C-pyruvate alone (Fig. 3A) , alanine was present in the TCM (Fig. 3B) . This is consistent with the observation that cancer cells secrete high levels of alanine as a means to dispose of excess nitrogen [36] . Some of the pyruvate produced from glucose may be shunted into anaplerotic reactions, thereby producing α-KG, glutamate, and alanine via alanine transaminase [37] . Thus, 13 Clabeled species of α-KG, glutamate, and alanine may have the potential to arise by exogenous pyruvate contributing to this reaction in a similar manner. Relatedly, the extra pyruvate provisioned to cells exposed to glucose and 13 C-pyruvate may enable MDA-MB-231 cells to better balance their energetic and biosynthetic needs, allowing for more robust growth (Fig. 2B) . These data suggest that CAFs may secrete pyruvate to provide MDA-MB-231 cells with important glycolytic and biosynthetic substrates, potentially releasing paracrine factors into the CCM that may modulate expression of glycolysis-promoting genes. Given the role of tumor-conditioned medium in differentiating MSCs [23] , the data presented in Fig. 3 demonstrate that factors in CCM and CAF-derived pyruvate may help complete a lactate-pyruvate metabolic loop between tumor cells and the TME.
CAFs modulate ROS in tumor cells
Tumors increase reactive oxygen species (ROS) production to promote pro-proliferative/pro-survival pathways and genetic mutagenesis important in adaptive growth [38] . However, excessive intracellular ROS causes irreparable genetic damage and induces cell death; accordingly, studies have shown that tumor cells may upregulate expression of antioxidant enzymes to combat excess ROS accumulation [39] . Thus, tumors balance the pro-growth and anti-survival effects of ROS in a seemingly paradoxical context in which high ROS production is maintained in the presence of high antioxidant levels.
Dysfunctional oxidative phosphorylation in glycolytic tumors results in the production of mitochondrial ROS, while the pentose phosphate arm and anaplerotic shunt of glucose metabolism produce reducing equivalents that power antioxidant systems [40] . As our data collectively indicate that pyruvate and other CCM factors may support and amplify glycolysis in MDA-MB-231 cells (Figs. 1-4) , we investigated in preliminary studies the role that the monocarboxylate or CCM may play in ROS modulation in these tumor cells. Fig. 5A shows the effect of exposing MDA-MB-231 cells for 5-5 mM pyruvate and/or 5 mM glucose on ROS accumulation, in the presence or absence of 25 µM tert-butyl hydrogen peroxide (H 2 O 2 ). Relative to nutrient depletion (Dep), this short-term exposure to pyruvate per se resulted in a moderate but statistically insignificant decrease in basal ROS levels, and significantly decreased ROS accumulation in the presence of glucose. The greatest pyruvate-mediated reduction in ROS levels was observed in the presence of H 2 O 2 , irrespective of the presence of glucose, indicating that short-term exposure to pyruvate may protect against ROS accumulation above basal levels. Exposure of pyruvate per se for 5 days markedly decreased ROS accumulation relative to Dep, and significantly attenuated ROS accumulation in the presence of glucose relative to pyruvate or glucose alone (Fig. 5B) . Glucose deprivation (Dep) is known to increase ROS production [41] , which is in agreement with the high ROS levels observed in this and the glucose-alone conditions (5 mM glucose was exhausted almost immediately relative to the 5 total days of the experiment [data not shown]). Collectively, these data are in accordance with aforementioned studies, which indicate that glucose metabolism attenuates ROS accumulation, and are consistent with investigations showing that pyruvate inactivates H 2 O 2 by directly decarboxylating the oxidant [42] . Relatedly, Tables S1 and S2 ). In MDA-MB-231 cells, CCM and H 2 O 2 increase synergistically ROS accumulation, while either condition alone does not increase significantly ROS levels (Supplementary Table S1 ). Over time, significant accumulation of ROS can be detected in all groups besides the MDAs+MDAs control group (Supplementary Table S2) , with ROS accumulation below 120 min significantly increasing by the addition of H 2 O 2 (Supplementary Table S2 Table S1 ) and (ii) changes over time within each group (Supplementary Table S2 ) was evaluated by two-way ANOVA with multiple comparison.
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exogenous pyruvate may function in concert with glucose to increase the mRNA expression of glucose-6-phosphosphate dehydrogenase (G6PD) (Fig. 5C ), the enzyme that catalyzes the first and rate-liming reaction that shunts glucose from the canonical glycolysis pathway to the pentose phosphate pathway [43] . Thus, stroma-derived pyruvate may act as an antioxidant while promoting glycolytic and biosynthetic functions in MDA-MB-231 cells to robustly increase their proliferation.
To determine if the ROS-attenuation effects of pyruvate can be observed in MDA-MB-231 cells exposed to CCM, we co-cultured the tumor cells with themselves or CAFs in transwell chambers for 4 days and subsequently interrogated for intracellular ROS levels. Interestingly, MDA-MB-231 s co-cultured with CAFs showed an increase in ROS accumulation (Fig. 5D) , concurrent with an increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1 (Nox-1) and manganese super oxide dismutase (Mn-SOD) gene expression (Fig. 5E ). While Nox-1 produces super oxide (SO), Mn-SOD scavenges SO radicals to produce H 2 O 2 , making Mn-SOD both a ROS producer and scavenger [44, 45] . Increased G6PD gene expression in MDA-MB-231 cells in response to CCM (Fig. 5E ) implies an increase in the reducing equivalent NADPH. This may play an important role in powering Nox-1 function [44] and in the reduction of glutathione sulfide to glutathione (GSH), a critical antioxidant that inactivates H 2 O 2 by reducing it to water [40] . Relatedly, GSH levels increased in MDA-MB-231 cells after co-culture with CAFs (Fig. 5F ). Consistent with the role of the Warburg effect in the reported nuanced management of ROS in tumor cells [45, 46] , our results indicate that CAFs may support this function by modulating the redox balance and enabling increased, stroma-mediated glycolysis in MDA-MB-231 cells.
Phloretin as a potential inhibitor of tumor-TME metabolic coupling
Our investigation into tumor-TME metabolic coupling identifies monocarboxylate transport, glycolysis, and ROS regulation as potential therapeutic targets. Flavonoids, a large group of polyphenols commonly found in the human diet, have been shown to inhibit lactate and pyruvate transport, glucose transport, and ROS accumulation [47, 48] . To determine which flavonoids would be appropriate for our studies, we first conducted in silico modeling studies of MCT1 to define likely binding pockets. As no crystal structure of human MCTs exist, a homology model of human MCT1 was built using the crystal structure of the E. coli glycerol-3-phosphate transporter (PDB ID 1PW4) [49] . The homology model was built via the single template approach using the MODELLER program 2 [50] . The model was subsequently used for in silico screening of small molecules. Electrostatic potential was mapped to the solvent-accessible surface area of MCT1. These sites, marked A and B in Fig. 6A -left panel, are distinguished by the difference in electrostatic potential. Site A is dominated by positive potential (colored blue), whereas site B is dominated by negative electrostatic potential (colored red). Site A is the region recognized for binding lactate. Subsequently, an interaction energy (Eint) analysis using the UCSF DOCK program 3 [51] was conducted for known compounds that bind site B, and thus, would limit stereotactic binding of lactate to Site A (Fig. 6A -right panel) . We calculated binding of the flavonoids quercetin, isoquercetin, p-phenylenediacetic acid, phloredzin, and phloretin; we found phloretin to have the lowest Eint (−50 kcal/mol), indicating that this flavonoid had the tightest binding potential of these 5 drugs to Site B.
To determine the relative cytotoxicity of these drugs, we tested their potency in attenuating MDA-MB-231 cell growth. After 6 days of exposure, phloretin and quercetin respectively decreased MDA-MB-231 cell growth by 20% and 60% (Fig. 6B) . Given phloretin's low cytotoxicity in MDA-MB-231 cells (relative to quercetin) and based on its favorable pharmacokinetics, its previous use in animal studies, and its low Eint values from MCT1 docking studies, we chose to use phloretin for subsequent studies.
To determine if phloretin affected monocarboxylate transport, glucose transport, and modulation of ROS levels, we treated stromal cells and MDA-MB-231 cells with the flavonoid. Phloretin exposure resulted in approximately 80% and 60% respective decrease in lactate uptake in MSCs and CAFs (Fig. 6C) , and approximately 50% and 95% respective decrease in pyruvate uptake (Fig. 6D ) and glucose uptake (Fig. 6E) in MDA-MB-231 cells. Additionally, basal ROS levels and H 2 O 2 -mediated ROS accumulation were inhibited by phloretin in MDA-MB-231 cells (Fig. 6F) . These data suggest that phloretin has the potential to significantly attenuate glycolysis and ROS accumulation in tumors, while disrupting monocarboxylate exchange between the tumor cells and the TME.
Given that metabolic and paracrine interplay may underlie TMEmediated support of tumor growth, determining the potency of phloretin in the context of the TME is important. To that end, we have initiated preliminary investigations into the effect of phloretin on MDA-MB-231 cell growth in the absence or presence of CCM. As presented in Fig. 6G , phloretin was significantly more cytotoxic to MDA-MB-231 cells in CCM than in controls. As monocarboxylate transport and glucose uptake is important for tumor cell metabolism [52, 53] , treatment with phloretin in combination with other drugs may allow for the use of this flavonoid at sub-IC 50 concentrations to minimize potential toxicity to host cells. As such, we queried the potential for phloretin to potentiate the toxicity of doxorubicin, a conventional chemotherapeutic. Phloretin cytotoxicity did not contribute to that of doxorubicin in complete medium but was additive in CCM (Fig. 6G) . We predict that in the poorly vascularized TME, glucose is limiting and tumors may therefore be more reliant on exogenous nutrients to maintain their proliferative potential. As such, the potency of conventional anti-cancer drugs may be increased in the presence of adjuvants, such as phloretin, that antagonize primary (glucose uptake) and secondary (monocarboxylate exchange) metabolic dependencies of tumors.
Discussion
Cross talk between tumor cells and other cellular components of their TME has been well studied in the context of cytokines, growth factors, extracellular matrix proteins, and other modulators of signal transduction [54] [55] [56] [57] . The recent resurgence in cancer metabolism research has focused investigations on how such factors may modulate glycolysis in tumors [58] . Using reports of intercellular nutrient cycling in muscles and brain [59, 60] as a guide to study potential lactate metabolite shuttling from the TME to tumor cells, our work reports that lactate oxidation in CAFs may provide pyruvate to MDA-MB-231 cells to support their biosynthetic and energetic needs. We also observed evidence of pyruvate-fueled anabolism in the presence of glucose as 13 C-labeled TCA intermediates were detected. The pathways involved in the metabolic fate of lactate and pyruvate were identified via the 13 C labeling of downstream metabolites using steady state measurements. The limitation of this approach is that a single time point measurement does not permit the calculation of synthesis or consumption rates or to model the relative contribution of the different metabolic pathways. These limitations can be overcome in future studies beyond the scope of this manuscript by using an MR-compatible cell perfusion bioreactor to measure the 13 C-labeling pattern time dependent in live cells [28] . While serial 1 H-decoupled 13 C MRS of live cells assesses cycling through Krebs cycle and associated pathways [28] , the addition of hyperpolarized 13 C MRS (a clinically applicable imaging modality) with its 10,000-fold boost in detection sensitivity would enable the direct measurement of the exchange reaction of lactate to pyruvate conversion in real time [61] [62] [63] [64] . Despite its advantages, hyperpolarized 13 C MRS also pose some challenges including the limited number of substrates that can be hyperpolarized, the expensive equipment and long time needed to hyperpolarize a substrate, and the quick loss of hyperpolarization during 13 C MRS at physiological conditions, requiring fast MRS acquisition methods [61] [62] [63] [64] . In our study, MDA-MB-231 cells, a representative model of TNBC, were more glycolytic and demonstrated higher oxidative metabolism [68] . However consistent with our results, Giatromanolaki et al. found based on the analysis of LDH isoenzymes in patient prostate cancer samples that tumor-associated fibroblasts use secreted lactate from glycolytic cancer cells to produce pyruvate to be used as continuous energy supply by the prostate cancer cells [69] . Further, in breast cancer patient samples, Choi et al. found that TNBC was predominantly associated with a Warburg-type (tumor: GLUT-1-and/or CA-IX-positive; stroma: Glut-1 and CAIX-negative) or mixedtype (tumor and stroma: GLUT-1-and/or CA-IX-positive) classification, while luminal breast cancer associated mainly with the reverse Warburg-type (tumor: Glut-1 and CAIX-negative; stroma: GLUT-1-and/or CA-IX-positive) and null-type (tumor and stroma: Glut-1 and CAIX-negative) classification [70] . These findings translated into the separation of disease-free and overall survival based on the metabolic tumor phenotype, with Warburg-type tumors associated with the worst and null-type tumors with the best outcome [70] . Our results are consistent with the findings by Choi et al. [70] , as MDA-MB-231 cells represent TNBC, the most aggressive breast cancer type associated with the worst outcome. Taken together, these data demonstrate the complex nature of the interplay between tumor and stromal cells and tumor metabolic heterogeneity, where no single cancer model covers all instances.
Pyruvate may also support the intracellular antioxidant arsenal used to manage elevated ROS levels, which correlated with increased CCM-mediated glycolysis. This study offers evidence of a reciprocal metabolic relationship between tumors and the TME that may be disturbed by phloretin, a flavonoid that inhibits monocarboxylate transport, glucose transport, ROS accumulation, and MDA-MB-231 cell growth.
Consistent with reports indicating that tumors upregulate ROS production in the context of elevated expression of antioxidants [35, 38, 39] , we have found that pyruvate decreased oxidant burden in MDA-MB-231 cells, while CCM increased glutathione (anti-ROS) levels and increased the expression of Nox-1 (pro-ROS), Mn-SOD (pro/anti-ROS), and G6PD (anti-ROS). The myriad of signaling pathways affecting ROS accumulation [71] and glycolysis [72] however undoubtedly confound determination of the causal versus correlative relationship between tumor metabolism and oxidant regulation.
In healthy mammalian cells, including hMSCs, utilizing oxygen results in the production of ROS which are kept at low intracellular levels by antioxidants realizing a highly reducing intracellular environment [13, 14] . As mitochondria consume most of cellular oxygen, they are considered a major cellular source of ROS [13] , although, the NOX enzyme family and other pathways, such as peroxisomal metabolism, cytochrome 450 metabolism, lysyl oxidases metabolism, and inflammation, may also contribute to cellular ROS [13] . Healthy cells undergoing oxidative stress may be damaged beyond repair and undergo apoptosis [13] .
Cancer cells tend to be more metabolically active than healthy cells and also demonstrate higher ROS production than their healthy counterpart [13] . As oxidative stress outweighs the capacity for repair, healthy cells may adapt by ramping up their antioxidant defense system or, if the damage is beyond repair, undergoing apoptosis [13] . Oxidative stress may mediate DNA damage, leading to genetic mutations, including mutations affecting the mitochondrial electron transport chain, that benefit cancer development [13, 14] . During cancer development, cells adapt to increased ROS by shifting oxidative mitochondrial metabolism toward glycolytic metabolism [13] .
Although the precise mechanism of the interplay between ROS and glycolysis modulation in breast cancer cells by CAFs is unclear at present, this study indicates that substrate availability is a growthlimiting constraint for glycolytic tumors. Our findings further indicate that Intercellular metabolic coupling between tumor cells and stromal cells may be a means by which tumors secure auxiliary sources of energetic and biosynthetic metabolites, which may synergize with paracrine signaling to robustly promote tumor growth. Indeed, a recent study by Huang et al. [73] supports our contention that pyruvate confers a growth and survival advantage to tumor cells in the nutrientdepleted TME. Additionally, an investigation of the expression of monocarboxylates in lung cancer and associated tumor stroma indicated an expression profile in which cancer cells express high levels of the lactate exporter MCT4 and the glucose importer GLUT1, while stromal cells show high expression of the lactate importer MCT1. Importantly, the study showed that MCT1 was negatively prognostic for disease-specific survival [74] . Such studies underscore the importance of the lactate-pyruvate shuttle as an attractive target for tumor therapy.
